Special Issue "Advancements in Cancer Immunotherapy beyond Checkpoint Blockade"
Deadline for manuscript submissions: 31 March 2024 | Viewed by 104
Interests: chronic illness; cancer chemoprevention; UV radiation; DNA damage; immunosuppression; microRNAs; epigenetics
Special Issues, Collections and Topics in MDPI journals
The advent of T-cell checkpoint inhibitors has revolutionized cancer therapy, leading to increased survival rates and even complete remission for numerous cancer patients. Despite their ability to enhance CD8+ T cell responses, other immune cell populations have been identified as potential targets for improving outcomes in cancer patients. Manipulating myeloid cells and other lymphocytes in pre-clinical models has demonstrated promising results in impeding cancer progression. This special issue aims to showcase the latest developments in immunotherapy targets that extend beyond CD8+ T cells.
Therefore, we would like to invite you all to contribute an original paper or a review paper on recent novel concepts based on basic and/or clinical research to understand role of various immune cells for the better management of cancers, a deadliest disease accounting over 10 million deaths worldwide, annually.
Dr. Ram Prasad
Dr. Vikash Kansal
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- T-cell function in cancer
- immune checkpoint blockade
- CD8+ T cell responses
- myeloid cells
- immunotherapy targets
- cancer progression